Research programme: 3CL protease inhibitors - Chongqing Fochon Pharmaceutical
Alternative Names: 3-chymotrypsin-like protease-Chongqing Fochon PharmaceuticalLatest Information Update: 27 Jan 2023
At a glance
- Originator Chongqing Fochon Pharmaceutical
- Class Antivirals; Small molecules
- Mechanism of Action Coronavirus 3C-like proteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 29 Nov 2022 Preclinical trials in COVID-2019 infections in China (unspecified route), prior to November 2022 (Chongqing Fochon Pharmaceutical pipeline, November 2022)